Harpoon Therapeutics

Company Profile

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct™ (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. The lead TriTAC product candidate, HPN424, is currently in a Phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer, or mCRPC. The second TriTAC product candidate, HPN536, is currently in a Phase 1/2a clinical trial initially focused on ovarian cancer.

Stock Quote

Price

Change

High

Events
Events

SEC Filings

Registration of certain classes of securities 12(b) of the Securities Exchange Act

SEC Filings

Registration of certain classes of securities 12(b) of the Securities Exchange Act

Search Investor Relations